The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Khabirov F.A.

Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'

Khaĭbullin T.I.

Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'

Granatov E.V.

Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'

Shakirzianova S.R.

GAUZ «Republic clinical neurology center», Kazan, Russia

Babicheva N.N.

Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'

Kochergina O.S.

Republican clinical diagnostic center for demyelinating diseases of the Ministry of Health of the Republic of Tatarstan GAUZ «Republic clinical neurology center», Kazan, Russia

Rakhmatullina E.F.

Neurology and manual therapy department of state medical academy, Kazan, Russia

Akhmedova G.M.

Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'

Aver'ianova L.A.

Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'

Yakupov M.A.

Republican clinical diagnostic center for demyelinating diseases of the Ministry of Health of the Republic of Tatarstan GAUZ «Republic clinical neurology center», Kazan, Russia

Sabirov Zh.F.

Republican clinical diagnostic center for demyelinating diseases of the Ministry of Health of the Republic of Tatarstan GAUZ «Republic clinical neurology center», Kazan, Russia

The results of an open comparative retrospective trial of the course of multiple sclerosis during treatment with infibeta and other interferon-beta bioanalogues and glatiramer acetate

Authors:

Khabirov F.A., Khaĭbullin T.I., Granatov E.V., Shakirzianova S.R., Babicheva N.N., Kochergina O.S., Rakhmatullina E.F., Akhmedova G.M., Aver'ianova L.A., Yakupov M.A., Sabirov Zh.F.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(3): 18‑26

DOI: 10.17116/jnevro20181183118-26

Views: 4123

Downloaded: 89

Download PDF (RU)
Contact the author
Table of contents

THE RESULTS OF AN OPEN COMPARATIVE RETROSPECTIVE TRIAL OF THE COURSE OF MULTIPLE SCLEROSIS DURING TREATMENT WITH INFIBETA AND OTHER INTERFERON-BETA BIOANALOGUES AND GLATIRAMER ACETATE
THE RESULTS OF AN OPEN COMPARATIVE RETROSPECTIVE TRIAL OF THE COURSE OF MULTIPLE SCLEROSIS DURING TREATMENT WITH INFIBETA AND OTHER INTERFERON-BETA BIOANALOGUES AND GLATIRAMER ACETATE

To cite this article:

Khabirov FA, Khaĭbullin TI, Granatov EV, et al. . The results of an open comparative retrospective trial of the course of multiple sclerosis during treatment with infibeta and other interferon-beta bioanalogues and glatiramer acetate. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(3):18‑26. (In Russ.)
https://doi.org/10.17116/jnevro20181183118-26

 
 
Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Long-term follow-up of adult patients with serial and status course of epileptic seizures. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):63-68
Open obse­rvational study with a retrospective analysis of the effi­cacy and tole­rability of aceclofenac in patients with acute non-specific low back pain. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):99-105
Comparing the effi­cacy of divo­zilimab and second-line treatments for rela­psing-remitting multiple scle­rosis in the Russian Fede­ration: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68
Effi­cacy and safety of fonturacetam in asthenia: a systematic review and meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):69-79
Short-term outcomes of mechanical and hand-sewn lapa­roscopic one-anastomosis mini-gastric bypass. Piro­gov Russian Journal of Surgery. 2024;(4):29-37
Deve­lopment of professional acti­vities of healthy life­style specialists without medi­cal education. Russian Journal of Preventive Medi­cine. 2024;(4):116-123
Effe­ctiveness of spinal traction in dege­nerative spine diseases. (A lite­rature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(4):60-69
Dete­rmination of factors influencing the medi­cal checkups effe­ctiveness of adult popu­lation living in rural areas. Russian Journal of Preventive Medi­cine. 2024;(10):23-28
Effi­cacy and safety of topi­cal anti­biotic therapy in patients with acute exte­rnal bacterial otitis: resu­lts of a retrospective study. Russian Bulletin of Otorhinolaryngology. 2024;(6):24-27
On the issue of choosing anesthesia methods: a comparison of gene­ral medi­cine and clinical dentistry. Stomatology. 2025;(1):76-80

Objective. To evaluate the efficacy and safety of the interferon beta-1b bioanalogue «infibeta» in the treatment of multiple sclerosis (MS) in comparison with other interferon beta bioanalogues and the generic drug glatiramer acetate. Material and methods. The data of 500 patients with MS treated with different disease-modifying drugs were analyzed. Patients of group 1 (n=95) received infibeta; group 2 (n=108) interferon beta-1b; group 3 (n=83) genfaxon-44; group 4 (n=109) sinnovex; group 5 (n=105) aksoglatiran FS. Results. In all groups, there was a significant decrease in the AARR and an increase in the EDSS score (p<0,05) after 12 and 24 months of treatment (p<0,05) with the best indicators in groups 1—3. After 12 months of treatment, the number of patients without signs of MRI activity was higher in groups 1—3 (48—61%) than in groups 4 and 5 (47, 43%, respectively) (p>0,05). After 24 months of treatment, the number of patients without signs of MRI activity decreased to 41–46% in groups 1—3, and more significantly in group 4 (27%). The percentage of NEDA-3 achieving patients did not significantly differ in the groups (23—32%) after 12 months of treatment. After 24 months of treatment the NEDA-3 declined more in group 4 (19%), least of all in groups 1 and 2 (27, 25%, respectively) (p>0,05). In most cases, the observed adverse events were mild or moderate. Flu-like syndrome was observed rarely in groups 1 and 4 (p<0,05). Injection reactions were observed most commonly in groups 3 and 5 (p<0,05). Conclusion. Infibeta, while retaining all the advantages of high-dose interferon beta, has the best tolerability profile, which makes it one of the optimal first line disease-modifying therapy for treatment of patients with MS.

Keywords:

infibeta
interferon beta-1b
genfaxon-44
synnovex
aksoglatiran FS
efficacy
safety
NEDA-3

Authors:

Khabirov F.A.

Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'

Khaĭbullin T.I.

Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'

Granatov E.V.

Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'

Shakirzianova S.R.

GAUZ «Republic clinical neurology center», Kazan, Russia

Babicheva N.N.

Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'

Kochergina O.S.

Republican clinical diagnostic center for demyelinating diseases of the Ministry of Health of the Republic of Tatarstan GAUZ «Republic clinical neurology center», Kazan, Russia

Rakhmatullina E.F.

Neurology and manual therapy department of state medical academy, Kazan, Russia

Akhmedova G.M.

Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'

Aver'ianova L.A.

Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'

Yakupov M.A.

Republican clinical diagnostic center for demyelinating diseases of the Ministry of Health of the Republic of Tatarstan GAUZ «Republic clinical neurology center», Kazan, Russia

Sabirov Zh.F.

Republican clinical diagnostic center for demyelinating diseases of the Ministry of Health of the Republic of Tatarstan GAUZ «Republic clinical neurology center», Kazan, Russia

List of references:

  1. Khabirov FA, Khaybullin TI, Granatov EV, Shakirzianova SR. Effect of cerebrolysin on remyelination processes in multiple sclerosis patients in stage of relapse regression. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2016;116(12):48-53. (In Russ.) https://doi.org/10.17116/jnevro201611612148-53
  2. Boyko AN, Lashch NY, Sharanova SN, Zakharova MN, Trifonova OV, Simaniv TO, Lysogorskaya EV, Guryanova OE, Kotov SV, Iakushina TI, Lizhdvoy VY, Belova YA, Khabirov FA, Babicheva NN, Khaibullin TI, Granatov EV, Averyanova LA, Sazonov DV, Odinak MM, Trinitatsky YV, Tsukurova LA, Sergeeva AI, Ivanov RA, Shustova MS. Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study. Zh Nevrol Psikhiatr im S.S. Korsakova. 2016;116: 10(2):61-67. (In Russ.) https://doi.org/10.17116/jnevro201611610261-67
  3. Dhib-Jalbut S, McFarland HF. Treatment of multiple sclerosis with interferon beta 1b. Baillieres Clin Neurol. 1997;6(3):467-480. PMID: 10101584.
  4. Boster A, Bartoszek MP, O’Connell C, Racke M. Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing — remitting multiple sclerosis. Ther Adv Neurol Disord. 2011;4(5):319-332. https://doi.org/10.1177/1756285611422108
  5. Ford CC, Johnson KP, Lisak RP, Panitch HS, Shifronis G, Wolinsky JS. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler. 2006;12(3):309-320. PMID: 16764344.
  6. Khabirov FA, Averyanova LA, Babicheva NN, Granatov EV, Khaybullin TI, Shakirzianova SR. Analysis of the effectiveness and safety of interferon beta-1a biosimilar for intramuscular injection in the treatment of multiple sclerosis. Modern medicine: neurology/psychiatry. 2016;1(1):21-24. (In Russ.)
  7. Popova EV, Boĭko AN, Vasil’ev AV, Davydovskaia MV, Zavalishin IA, Kotov SV, Krotenkova MV, Khachanova NV, Sharanova SN, Shchur SG, Iakushina TI. Results of a comparative clinical trial of the Russian Β — interferon-1b bioanalogue (infibeta). Zh Nevrol Psikhiatr im. S.S. Korsakova. 2012;112(5):56-61. PMID: 22951783. (In Russ.)
  8. Khabirov FA, Babicheva NN, Khaĭbullin TI, Aver’ianova LA, Granatov EV, Akhmedova GM. Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2012;112:9(2):113-122. PMID: 23235429. (In Russ.)
  9. Bakhtiiarova KZ, Bragina OV, Vlasov YaV, Greshnova IV, Evdoshenko EP, Ivanishenkova EI, Kairbekova EI, Karnaukhova EN, Korotkevich NA, Leliukhina AV, Protasov IS, Rybina EV, Sazhnev AI, Skoromets AA, Soldatova OA, Trinitatskiĭ YuV, Fedianin AS, Chelnokova SN, Shabanova VD, Sharipova RR, Shchegol’kova EA, Iampol’skaia-Gosteva IA. Experience of using genfaxon for treating patients with relapsing-remitting multiple sclerosis in the Russian Federation. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2014; 114(8):39-45. PMID: 25345629. (In Russ.)
  10. Khabirov FA, Khaybullin TI, Granatov EV, Babicheva NN, Aver’ianova LA, Shakirzianova SR. Results of an open-label comparative randomized clinical trial of Axoglatiran FS (F-Sintez, Russia) efficiency and safety in comparison with Copaxone-Teva (Teva Pharmaceutical Industries Ltd., Israel) in patients with relapsing-remitting multiple sclerosis. Neuromuscular diseases. 2016;6(4):28-36. (In Russ.) https://doi.org/10.17650/2222-8721-2016-6-4-28-36
  11. Borets OG, Govorukhina NF, Zverev KV, Boiko AN. A comparison analysis of the use of intravenous β-interferon-1a 30 mcg and subcutaneous β-interferon-1a 44 mcg in routine clinical practice of treatment in patients with multiple sclerosis. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2016;116:2(2):63-67. (In Russ.) https://doi.org/10.17116/jnevro20161162263-67
  12. Kasatkin DS, Spirin NN, Boiko AN, Stepanov IO, Spirina NN, Baranova NS. The results of an open prospective study of β-interferon biosimilars (an Yaroslavl’ cohort). Zh Nevrol Psikhiatr im S.S. Korsakova. 2016;116:2(2):68-73. (In Russ.) https://doi.org/10.17116/jnevro20161162268-73
  13. Khabirov FA, Khaibullin TI. Multiple sclerosis: modern principles of diagnostic and treatment: monography. Kazan. 2017. (In Russ.)
  14. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone MA, Weber A, Zipp F, Miterski B, Epplen JT, Oturai A, Sørensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Rubio J, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sá M, Salemi G, Savettieri G, Hillert J, Compston DA. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology. 2005;64(7):1144-1151. https://doi.org/10.1212/01.WNL.0000156155.19270.F8
  15. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Published: May 28, 2009 (v4.03: June 14, 2010). https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
  16. D’Amico E, Leone C, Zanghì A, Fermo SL, Patti F. Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study. J Neurol. 2016;263(9):1802-1809. https://doi.org/10.1007/s00415-016-8207-z

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.